[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"crpc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:crpc":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100563027","phase-2-castrate-resistant-prostate-cancer-enhertu-therapy-100563027",false,"NCT06610825","Castrate Resistant Prostate Cancer Enhertu Therapy","A Phase II Clinical Trial to Evaluate the Efficacy and Safety of Fam-Trastuzumab Deruxtecan-Nxki (T-DXd) as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma","CaRPET","Inclusion Criteria:\n\n* Pathologically confirmed adenocarcinoma of the prostate\n* Diagnosis of mCRPC\n* Documented progression on androgen deprivation and novel hormonal agents, with or without progression on taxane containing regimen\n* Ongoing ADT to maintain serum testosterone levels below 50 ng\u002FdL\n* Formalin fixed paraffin embedded tumor tissue for HER2 immunohistochemistry\n* Life expectancy 6 months\n* ECOG 0 or 1\n* LVEF at least 50%\n* Adequate Blood Clotting function\n* Adequate Organ and Bone Marrow function\n* Adequate Renal function\n* Adequate Hepatic function\n\nExclusion Criteria:\n\n* History of interstitial lung disease or pneumonitis requiring steroids\n* Significant coronary vascular disease\n* Previous exposure to HER2 targeted therapy","MALE","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Use of Enhertu as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma.",[27,28,29],"Prostate Cancer Metastatic","Prostate Cancer","CRPC",[31,32,33,34,35,36,37],"prostate cancer","metastatic prostate cancer","Enhertu","HER2 positive","Trastuzumab deruxtecan","crpc","phase 2","RECRUITING","2026-04-06",{"date":41,"type":42},"2026-04-13","ACTUAL",{"date":44,"type":42},"2025-03-05",{"date":46,"type":21},"2028-10",{"name":48,"class":49},"Washington D.C. Veterans Affairs Medical Center","FED",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":58,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":72,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":50},"100415211","phase-1-a-first-in-human-jab-8263-in-adult-patients-with-advanced-tumors-100415211","NCT04686682","A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors","A Phase I\u002FIIa, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-8263 in Adult Patients With Advanced Malignant Tumors","Inclusion Criteria:\n\n* Subjects must meet all the following criteria in order to be included in the research study:\n\n  1. Subject must be ≥18 years-of-age at the time of signature of the informed consent form (ICF).\n  2. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.\n  3. Subjects with histologically or cytologically confirmed advanced solid tumors which have progressed despite standard therapy(ies), or are intolerant to standard therapy(ies), or have a tumor for which no standard therapy(ies) exists.\n  4. Subjects with recurrent\u002Frefractory AML according to WHO 2016\n  5. Subjects with life expectancy ≥3 months.\n  6. Patients with solid tumor must have at least one measurable lesion as defined by RECIST v1.1.\n  7. Patients who have sufficient baseline organ function.\n\nExclusion Criteria:\n\n1. History (≤3 years) of cancer that is histologically distinct from the cancer under study.\n2. Known serious allergy to investigational drug or excipients\n3. Active brain or spinal metastases\n4. History of pericarditis or Grade ≥2 pericardial effusion\n5. History of interstitial lung disease.\n6. History of Grade ≥2 active infections within 2 weeks\n7. Known human immunodeficiency virus (HIV) infection\n8. Seropositive for hepatitis B virus (HBV)\n9. Seropositive for hepatitis C virus (HCV), or HCV-RNA viral levels are not detectable.\n10. Any severe and\u002For uncontrolled medical conditions\n11. History of myocardial infarction, unstable angina pectoris, coronary artery bypass graft, or cerebrovascular accident\n12. Impaired cardiac function or clinically significant cardiac diseases\n13. QTcF \\>470 msec at screening\n14. History of medically significant thromboembolic events or bleeding diathesis\n15. Unresolved Grade \\>1 toxicity\n16. History of malignant biliary obstruction\n17. Pregnant or breast-feeding","ALL",{"count":60,"type":21},152,[62,24],"PHASE1","This is a Phase 1\u002F2a, first-in-human, open-label study of JAB-8263, this study has two parts: solid tumor dose escalation and expansion study and hematology tumor dose escalation and expansion study.\n\nThese two parts will determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and assess the DLT of JAB-8263 in treatment with patients with advanced solid tumors and hematology tumors separately. 30 subjects each will be enrolled.",[65,66,29,67,68,69,70,71],"NSCLC","SCLC","ESCC","Ovarian Carcinoma","AML","MF","Malignant Tumor",[73,74],"BET inhibitor","Bromodomain and Extra-terminal","2026-01-08",{"date":77,"type":42},"2026-01-09",{"date":79,"type":42},"2021-05-07",{"date":81,"type":21},"2028-07",{"name":83,"class":84},"Jacobio Pharmaceuticals Co., Ltd.","INDUSTRY"]